ISSN: 2633-4828 Vol. 5 No.4, December, 2023

International Journal of Applied Engineering & Technology

EHENSIVE REVIEW OF BACTERIOCIN PRODUCTION, MECHANISM OF ACTION AND POTENTIAL APPLICATION

S. B. Sabale[1], P. V. Deshmukh[2]

[1]Ph.D Student Punyashlok Ahilyadevi Holkar Solapur University

[2]Assistant Professor, Department of Microbiology, Pratapsinh Mohite-Patil Mahavidyalaya Karmala

Corresponding author:Smitasabale15@gmail.com

ABSTRACT

Bacteriocins are naturally occurring antimicrobial compounds produced by bacteria, characterized by their ability to selectively inhibit the growth of closely related bacterial strains and, in some cases, different species. These compounds have gained considerable attention due to their potency, specificity, and potential applications in food preservation, medicine, agriculture, and biotechnology. Bacteriocins are classified into several types based on their structural features and mechanisms of action. Their production is regulated by bacterial genetic material and is often triggered by environmental conditions or microbial competition. The primary modes of action of bacteriocins include membrane permeabilization, enzyme inhibition, and interference with cell wall synthesis, resulting in cell death. Bacteriocins have been utilized as natural preservatives in the food industry, as potential alternatives to traditional antibiotics in medicine, for controlling plant pathogens in agriculture, and for molecular selection processes in biotechnology. Due to their specific action and lower risk of resistance development, bacteriocins offer a promising alternative or complement to conventional antibiotics, particularly in light of the rising antibiotic resistance. Further research into bacteriocin production, mechanisms, and applications is expected to enhance their utility across various industries, contributing to improved public health and safety. Extensive research has been conducted on the production, mechanism of action, and applications of bacteriocins in the food industry. However, there is still a lack of understanding regarding their potential use in other industries. This review aims to provide an overview of the current state of knowledge on the production, mechanism of action, and applications of bacteriocins, and to identify potential gaps in the literature that can be addressed in future research. Bacteriocins have the potential to be utilized in various industries beyond food, including pharmaceuticals and cosmetics, and additional research is necessary to fully explore their potential applications

***Keywords**: Bacteriocins, Antimicrobial, pharmaceuticals*

INTRODUCTION

Bacteriocins are antimicrobial peptides created by ribosome synthesis. They have strong bactericidal effects on closely related strains of bacteria and occasionally on strains from different genera. With the ability to hinder or eliminate rival bacteria from their surroundings, these peptides constitute a broad class of naturally occurring antibiotics that provide producer organisms with a notable edge in microbial competition. Bacteriocins are categorized according to their molecular weights, structures, biochemical characteristics, and action methods. Class I (lantibiotics), Class II (non-lantibiotic peptides), and Class III (large, heat-labile proteins) are the three primary classes that are often divided.

Small peptides known as class I bacteriocins or lantibiotics are distinguished by the post-translationally inserted presence of peculiar amino acids such as lanthionine and methyllanthionine. These heat-stable peptides function against microorganisms by blocking vital enzymes or creating holes in the target cell membrane. Because of its effectiveness against a wide range of gram-positive bacteria, nisin, a well-known antibiotic generated by *Lactococcus lactis*, is frequently used as a food preservative (1).

The tiny heat-stable peptides, known as class II bacteriocins, do not include any odd amino acids. Based on their composition and purpose, numerous subclasses were further separated. Subclass IIa, often referred to as pediocin-like bacteriocins, is composed of peptides that bind to specific receptors on the cell membrane to cause pore

formation and cell death. In contrast, two peptides are required for subclass IIb bacteriocins to function and rupture the cell membrane (2).Larger proteins, known as class III bacteriocins, are heat-labile, meaning that heating causes them to lose activity. These bacteriocins can break down vital bacterial.

Components, such as peptidoglycans or nucleic acids, frequently exhibit enzymatic activity. Compared to the smaller, more stable bacteriocins of Classes I and II, the use of Class III bacteriocins is more restricted because of their larger size and heat-lability(3).

The goal of this review is to present a thorough analysis of bacteriocins, with an emphasis on their genetic regulation, structural diversity, and production methods. We will examine the mechanisms of action, the resistance mechanisms that target organisms have evolved, and the wide spectrum of possible uses in agriculture, medicine, and food preservation. We intend to provide a comprehensive overview of bacteriocins and their significance in future antimicrobial tactics by combining existing research and identifying upcoming trends. This review is organized into parts that go into great detail about the ecological roles and methods of action of each bacteriocin after defining and classifying them. The practical uses of bacteriocins will be discussed in later sections, supported by current research findings. The final section addresses prospects and possible obstacles for the sector.

PRODUCTION AND BIOSYNTHESIS

Geneticbasis ofbacteriocinproduction

The bacteriocin operon is a group of genes that genetically encodes and controls the synthesis of bacteriocins, which are antimicrobial peptides produced by bacteria. Genes involved in bacteriocin production, immunity, regulation, and secretion are usually found in thisoperon. While immunity genes confer bacterial resistance to their bacteriocins, frequently by encoding specific immunity proteins or altering target sites to prevent self-damage, synthesis genes encode pre-peptides that undergo post-translational modifications to become active bacteriocins (5). Through two-component systems or quorum sensing methods, regulatory genes regulate the expression of bacteriocin-related genes frequently in response to environmental signals (6). The process of exporting mature bacteriocins out of the cell is facilitated by transport systems, usually ATP-binding cassette transporters, which are encoded by secretory genes. Furthermore, bacteriocin gene clusters can be found on mobile genetic elements such as plasmids or transposons, which facilitate horizontal gene transfer between bacteria and contribute to the spread of bacteriocin production across bacterial populations (4). Recent studies have also highlighted the role of regulatory RNAs and other epigenetic factors in modulating bacteriocin gene expression, adding another level of complexity to the genetic regulation of bacteriocin production (2).

Control of bacteriocin production

The intricate process of controlling bacteriocin biosynthesis involves several genetic and environmental variables, ensuring that these antimicrobial peptides are synthesized only under the right circumstances. Quorum-sensing mechanisms and two-component systems (TCSs) play major roles in mediating this regulation. TCSs are composed of a response regulator that modifies gene expression in response to environmental inputs and a membrane-bound sensor kinase that detects these signals (7). For example, in *Lactococcus lactis*, TCS, which consists of the response regulator NisR and histidine kinase NisK, regulates the expression of genes involved in nisin biosynthesis in response to nisin, thus establishing a feedback loop that controls production (8).

Another important regulatory method is quorum sensing (QS), which is based on the synthesis and identification of signaling molecules known as autoinducers. Coordinated expression of bacteriocin genes throughout a bacterial population is triggered when the concentration of these molecules reaches a threshold. According to Perez *et al.,* (2015), this approach ensures that bacteriocins are produced at high cell densities, increasing their effectiveness in microbial competition (9).

Furthermore, global regulatory proteins such as sigma factors and regulatory RNAs such as short RNAs (sRNAs) are important in regulating the expression of bacteriocin genes in response to different growth conditions and

stressors (11). By integrating several environmental signals, bacteria can modify the synthesis of bacteriocins in response to these regulatory components. Moreover, by changing the accessibility and chromatin structure of the transcriptional machinery, epigenetic changes such as DNA methylation can also affect the expression of the bacteriocin gene (10).

ProductionMethodsofBacteriocins:Fermentation andHeterologousExpression

Although there are several techniques for producing bacteriocins, fermentation, and heterologous expression are the most often used. To increase production, the traditional method of fermentation requires the cultivation of bacteriocin-producing bacteria under specific circumstances. This procedure depends on maximizing variables including temperature, aeration, nutrient availability, and pH. To sustain a high output, *Lactococcus lactis* produces nisin in batch or fed-batch fermenters, where the pH is regulated to approximately 6.5 and glucose is supplied steadily. (12).

In addition, post-translational modification systems that are necessary for bacteriocin activity but might not be found naturally in the host organism can be included in heterologous hosts by engineering. Furthermore, advances in synthetic biology have facilitated the development of optimal gene constructs and expression systems that further improve bacteriocin production. For instance, accurate insertion of bacteriocin gene clusters into ideal genomic locations has been made possible by CRISPR/Cas9-mediated genome editing, leading to the development of stable and high-yield production strains (14). Furthermore, co-expression of immune proteins can boost total yield by shielding the host organism from the harmful effects of the bacteriocins generated (15).

MECHANISMOF ACTION:

Antimicrobial peptides known as bacteriocins, which are produced by bacteria, work against target bacteria using a variety of methods, chiefly the development of pores in cell membranes and the inhibition of cell wall manufacturing. One of the most prevalent ways in which bacteriocins work is through the creation of pores in the target cell membranes. These pores disrupt membrane integrity, which in turn causes ion leakage, depolarization, and ultimately cell death. For instance, one well-known lantibiotic, nisin, binds to lipid II, an important precursor in the formation of cell walls, and creates gaps in the bacterial membrane that allow vital ions and metabolites to quickly escape (16). Suppression of cell wall production is another important mechanism of action. The incorporation of lipid II into the developing cell wall is efficiently blocked by bacteriocins, such as mersacidin and actagardine, causing cell lysis and preventing cell wall production (17). Because the cell wall is an essential structural element of gram-positive bacteria, this method works very well against them.

In addition to these basic mechanisms, bacteriocins have the ability to interfere with various cellular functions. Certain bacteriocins obstruct the synthesis of proteins, RNA, and DNA. For example, microcin B17 stops bacterial growth by inhibiting DNA gyrase, an enzyme necessary for DNA replication (18). Some bacteriocins can cause target cells to produce autolysins, which are internal enzymes that break down the cell wall and cause cell death (19). The interaction of bacteriocin with specific receptors or cell surface molecules exclusive to certain bacterial species is usually the cause of this specificity. For instance, *Lactococcus lactis* produces lacticin 3147, which works well against other lactic acid bacteria (20). Recent developments in protein engineering and synthetic biology have made it possible to modify bacteriocins to alter their range of action, either by reducing off-target effects or extending it to target additional infections (21). For bacteriocins to be used effectively in a variety of settings, such as food safety, medicine, and agriculture, where specialized antimicrobial approaches are frequently needed to address particular microbiological issues, it is imperative to comprehend their spectrum of activity.

RESISTANCEMECHANISMSANDPOTENTIALDEVELOPMENTOFRESISTANCETOBACTERIOCINS

Bacterial resistance can develop through various methods, making bacteriocins vulnerable despite their strong antibacterial properties. To maximize the utilization of bacteriocins in industrial and therapeutic applications, it is imperative to understand their resistance mechanisms. Alteration of target molecules that bacteriocins interact with is one of the main resistance mechanisms. For example, bacteria can change the structure of lipid II, which is

the target of several antibiotics, including nisin. This can reduce bacteriocin binding affinity and, consequently, lessen its effectiveness (22).By producing more extracellular proteases that break down bacteriocins before they reach their target, bacteria can also become resistant to certain antibiotics. According to Moll *et al.,,* (1996), this enzymatic breakdown successfully reduces the amount of active bacteriocins in the environment, allowing resistant bacteria to endure and spread (24).

Furthermore, as some resistant strains of *Listeria monocytogenes* have shown, modifications in the content or structure of membranes can also confer resistance by decreasing the insertion and pore-forming capabilities of bacteriocins (25). Resistance genes are spread throughout bacterial populations, primarily through horizontal gene transfer, or HGT. Resistance genes can be transferred across different bacterial species using plasmids, transposons, and bacteriophages, which hastens the dissemination of resistance features (26). This rapid development of resistance highlights the importance of monitoring and controlling the use of bacteriocins to reduce the possibility of resistance. Furthermore, because of the possibility of resistance, bacteriocins must be used in conjunction with other antimicrobials or as a rotating regimen to reduce selective pressure and the establishment of resistant bacteria. To maintain the ongoing effectiveness of these important antimicrobial medicines, research has endeavored to understand the molecular mechanisms underlying resistance to bacteriocins and devise methods to avoid or counteract resistance.

CLASSIFICATION AND TYPES

Examples of well-characterized Bacteriocin

Numerous well-characterized bacteriocin-strong antimicrobial peptides produced by bacteria include nisin, pediocin, and colicin. Because of their distinct structures, modes of action, and uses, these bacteriocins have been the subject of extensive research. One of the most investigated lantibiotics is nisin, which is produced by *Lactococcus lactis*. It contains unique amino acids that are produced by post-translational changes, such as methyllanthionine and lanthionine. To disrupt cell wall biosynthesis and create gaps in the bacterial membrane, nisin principally exerts its antimicrobial activity by binding to lipid II, a key precursor in the creation of bacterial cell walls (16). Nisin is very efficient against gram-positive bacteria, such as *Listeria* and Staphylococcus species, owing to its dual method of action. Owing to its effectiveness and safety, it is frequently used as a food preservative that has been approved by the FDA and EFSA (34). *Pediococcus acidilactici* produces Pediocin PA-1, a Class IIa bacteriocin with potent anti-*Listeriamonocytogene* activity. The target cell membrane is perforated by this heat-stable peptide, resulting in cell leakage and death. The N-terminus of the peptide has a conserved YGNGV sequence that is essential for its function (35).

Pediocin PA-1 holds great promise for improving food safety in the food sector by inhibiting the growth of *Listeria* in dairy and meat products (15). Colicins, which are larger protein bacteriocins that target related bacteria, are produced by *Escherichia coli*. Colicin E1, for instance, disrupts the membrane potential of target cells by forming voltage-gated channels in their inner membranes, which results in cell death (36). These well-studied bacteriocins serve as models for comprehending the various ways in which bacteriocins work, as well as their possible uses in biotechnology, medicine, and food preservation. Further investigation of these and other bacteriocins is likely to increase their usefulness and efficacy across a range of domains.

POTENTIAL APPLICATIONS

Bacteriocins, antimicrobial peptides generated by bacteria, can inhibit the growth of comparable or closely related bacterial strains. Probiotics, antibiotic treatments, food preservation, and medicinal applications are just a few of the many areas in which they may be valuable. Here is a thorough examination of their possible uses.



Figure 1: An Overview of Bacteriocin's Uses [37]

1. Food Preservation and Safety

A promising strategy for improving food safety and preservation is the use of bacteriocins. By inhibiting harmful and spoiling bacteria in food goods, these peptides can prolong shelf life and lower the risk of foodborne infections.

- Dairy Product Preservation: The dairy sector currently uses bacteriocins, such as nisin, extensively to prevent the growth of harmful bacteria, such as *Listeria monocytogenes* and rotting organisms. The FDA and EFSA have approved nisin for use in cheese and canned goods, among other foods.
- Pathogen Control: Bacteriocins have been studied as naturally occurring meat and seafood preservatives. One substance that works well against *Salmonella* and *Listeria* in meat products is pediocin, which is made from *Pediococcusacidilactici*(38).
- Biofilm Prevention: According to Sokovic *et al.,* (2015), certain bacteriocins can prevent harmful bacteria from forming biofilms on food-processing equipment, enhancing safety and hygiene in food-manufacturing settings.

2. Probioticsand GutHealth

Bacteriocins are advantageous in probiotic applications, where they improve gut health by influencing microbial ecology.

- Pathogen-Selective Pressure: Bacteriocin-producing probiotic strains can inhibit harmful bacteria in the gastrointestinal tract. For example, a bacteriocin produced by *Lactobacillus rhamnosus* GG inhibits pathogens such as *Escherichia coli* and *Clostridium difficile*.
- Preserving Gut Microbiota Balance: By favoring beneficial bacteria and selectively suppressing harmful bacteria, bacteriocins included in probiotics can help preserve a balanced gut microbiota (39).
- Therapeutic use in gut disorders: Bacteriocins may be used as therapeutic agents for the treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) (40). 2. Interest in bacteriocins as substitutes for antibacterial agents has grown as antibiotic resistance has increased. They may be superior to conventional antibiotics owing to their distinct modes of action and selectivity.

3. Antimicrobial Agents

Interest in bacteriocins as substitute antibacterial agents has grown as antibioticresistance has increased. They may be superior to conventionalantibiotics due to theirdistinctmodes ofactionand selectivity.

- Targeted Action: Bacteriocins frequently have narrow spectra, allowing them to selectively target particular bacterial species while sparing the beneficial microbiota. According to Ganzle *et al.,,* this selectivity can lower the likelihood of broad-spectrum antibiotic resistance (15).

- Combination Therapy: Bacteriocins can be used in conjunction with conventional antibiotics to increase their efficacy and reduce resistance. For instance, it has been demonstrated that nisin and traditional antibiotics work synergistically to combat resistant germs (41).
- Creation of Novel Therapies: Studies on the application of bacteriocins to diseases caused by drug-resistant organisms are currently underway, potentially providing a fresh line of defense against infections that are becoming increasingly resistant (42).

4. Biomedical Applications

Bacteriocins have prospective applications in the biomedical field for a range of therapeutic applications, including cancer treatment and wound healing.

- Wound Healing: It has been demonstrated that bacteriocins, such as nisin, aid in the healing of chronic wounds and prevent infections. Their antibacterial properties can lessen inflammation and bacterial burden, promoting a quicker and more efficient recovery.
- Cancer Treatment: Studies on specific bacteriocins have shown that they are cytotoxic to cancer cells. For example, the ability of enterocytes from *Enterococcus* species to kill cancer cells while preserving healthy cells has been studied (43).
- Immunomodulation: According to Kim *et al.,* (2020), bacteriocins may play a role in immune system modulation by strengthening immune responses against infections and cancers (44).

CHALLENGES AND LIMITATIONS

Although bacteriocins are intriguing antimicrobial peptides with a wide range of uses, several issues and restrictions must be resolved before their full potential can be realized. Important topics such as manufacturing and purification, safety problems and regulatory frameworks, and stability and activity are covered in this review.

1. Stability and activity issues of bacteriocins

a. **Stability of Bacteriocin**: The effectiveness of bacteriocins can be affected by environmental factors, such as pH, temperature, and proteolytic enzymes. The deterioration of many bacteriocins in harsh environments restricts their use for various applications.

- Temperature Sensitivity: The use of certain bacteriocins in heat-processed foods is complicated by the fact that they become inactive at high temperatures. For instance, long-term heat exposure can cause the disintegration of nisin, which is frequently used in food preservation.
- pH Sensitivity: Many bacteriocins are affected by pH in terms of their activity. According to Ganzle *et al.,* (2018), nisin is useful at acidic pH values but may become inert at neutral or alkaline pH levels (45).
- Proteolytic Degradation: The efficacy of bacteriocins can be diminished by proteases found in the human gut and the environment. This is particularly problematic for probiotic and therapeutic applications (46).

b. Activity Limitations:

Bacteriocins have a limited range of action because they primarily target particular strains of bacteria. This restriction may limit their applications when a more comprehensive antibacterial response is required.

2. Production and purification challenges:

a. Production:

The large-scale synthesis of bacteriocins can present difficulties because the fermentation processes are intricate and the bacteria that produce them require particular growing conditions.

- Fermentation Problems: It is difficult and costly to optimize fermentation conditions for the high-yield manufacture of bacteriocins. For example, boosting the output of bacteriocins requires adjusting fermentation

conditions and nutritional media.

- Strain Variability: Maintaining consistency in production quality can be challenging when there are large variations in production efficiency among the bacterial strains (47).

b. Purification:
Bacteriocins from fermentation broths are difficult and expensive to purify. This purification procedure may be hampered by the presence of additional proteins and metabolites.

- Purification complexity: Advanced methods such as chromatography, which can be costly and labor-intensive, are required to extract and purify bacteriocins from complex mixtures.
- Yield and Cost: The viability of large-scale application of bacteriocins is affected by the purification process, which is sometimes expensive compared to the yield of the compounds (47).

3. Regulatory Framework and Safety Concerns

a. Regulatory Challenges:
Bacteriocins may require a complicated regulatory approval procedure, which varies according to application and location. Different standards apply to bacteriocins used in food, pharmaceuticals, and other uses, according to regulatory authorities such as the FDA and EFSA.

- Approval Procedures: Specific regulatory approval is needed for each use of bacteriocins, and this process entails extensive testing and validation. For example, nisin is permitted for use in food products; however, further research is required for therapeutic or medical purposes (45).
- Standardization: The absence of established protocols for the testing and assessment of bacteriocins can result in discrepancies in regulatory evaluations.

b. Safety Concerns:
Although bacteriocins are typically regarded as harmless, careful safety assessments are necessary before their use in humans or animals. Allergic responses and inadvertent effects on the microbiota are examples of potential hazards.

- Allergenic Potential: It is important to conduct a thorough investigation into the possibility that some bacteriocins may trigger allergic reactions in sensitive individuals (47).
- Effect on Microbiota: It is unclear how long-term use of bacteriocins affects the human microbiota. They may have an impact on beneficial microbial communities in addition to harmful bacteria (45).

FUTURE PERSPECTIVES:
Research on bacteriocins, including how they are made, how they work, and how they are used, shows room for growth and innovation. Future perspectives that could influence the discipline are emerging as the research continues. These include developing new applications and research areas, improving genetic engineering and production techniques, and using bacteriocins to address global health issues.

1. Advances in Genetic Engineering and Production Methods
a. Genetic engineering of bacteriocin producers: Developments in genetic engineering could lead to better bacteriocin synthesis and characteristics. Methods such as synthetic biology and CRISPR-Cas9 can be used to improve the stability, production, and specificity of bacteriocins.

- Optimizing Production Strains: More economical and productive strains of bacteriocin-producing bacteria can be produced using genetic engineering. Production yields can be increased by genetically modifying strains of*Lactococcuslactis* to overexpress bacteriocins.
- Enhanced Stability: Bacteriocins with better stability under a range of environmental conditions can also be

engineered via genetic methods. For example, the tolerance of bacteriocins to heat and pH fluctuations can be increased by modifying their amino acid sequences using site-directed mutagenesis (42).

b. Novel Production Methods: The efficiency and scalability of bacteriocin manufacturing are predicted to increase with the development of fermentation technology and process optimization.

Continuous Fermentation: Compared with batch fermentation, the use of continuous fermentation systems may improve bacteriocin production efficiency. This method lowers the cost and boosts the yield by enabling continuous bacteriocin synthesis and harvesting.

Alternative production platforms**:** Research on platforms such as algae or yeast could open up new ways to produce bacteriocins. These platforms may reduce production costs and simplify scaling up (48).

2. Emerging Applications and Areas of Research

a. Therapeutic Applications: Research on the potential of bacteriocins as medicinal agents is fascinating. Their use may extend beyond probiotics and food preservation in future research.

- Cancer Therapy: Studies examining the anticancer capabilities of bacteriocins are promising. Future research should examine their application in targeted cancer therapy, either in isolation or in conjunction with already available medications (48).
- Wound Healing: Applications of bacteriocins in wound healing have shown promise. Subsequent investigations should concentrate on creating topical medications or dressings based on bacteriocin to hasten healing and prevent infection.

b. Environmental and agricultural applications: Bacteriocins can be used in environmental management and agriculture.

- Agricultural Use: Bacteriocins can be used as organic insecticides or soil conditioners to inhibit plant diseases and enhance plant health. Research on their function in plant disease biocontrol is just beginning.
- Bioremediation: The application of bacteriocins in bioremediation procedures may offer novel approaches for environmental cleanup. In contaminated environments, bacteriocins may assist in controlling microbial contamination (49).

3. Potential for Bacteriocins to Address Global Health Challenges

a. Antibiotic Resistance: The emergence of antibiotic-resistant microorganisms is a serious threat to global health. Bacteriocins are possible substitutes for conventional antibiotics.

- Fighting Resistant Strains: Research should concentrate on creating novel antimicrobial compounds called bacteriocins to combat diseases resistant to several drugs. To overcome these resistance difficulties, they may be used because of their selectivity and efficiency against particular bacterial strains.
- Complementary to Antibiotics: Bacteriocins may be used in conjunction with antibiotics to increase efficacy and lower resistance. According to Cleveland *et al.,* (2021), this combinatorial method may be useful for treating illnesses caused by resistant bacteria (49).

b. Global Health and Nutrition: Bacteriocins may be useful for enhancing nutrition and general health.

- Nutritional Supplements: Adding bacteriocins to functional meals or dietary supplements may assist in controlling gut health and protecting against infection. This may be especially helpful in areas where access to healthcare is scarce.
- Public Health: Bacteriocins may be employed in public health initiatives to prevent and manage bacterial illness epidemics. Improvements in general public health may result from their application to environmental cleanliness and food safety (49).

CONCLUSION

Bacteriocins are a class of antimicrobial peptides that show great promise in several fields, including medicine, agriculture, and food preservation. They are useful tools for regulating microbial populations because of their various modes of action, including hole formation, suppression of cell wall synthesis, and selectivity against target bacteria. Although the genetic foundation and regulation of bacteriocin synthesis are intricate, biotechnological treatments present options to improve yield and stability. The possibility of resistance among target organisms and technological difficulties in manufacturing and application must be carefully considered. To fully utilize the potential of bacteriocins and ensure that they can be successfully included in tactics for fighting antibiotic-resistant bacteria and guaranteeing food safety, further study and innovation are required.

FUTURE OUTLOOK AND POTENTIAL IMPACT

The future of bacteriocins is promising, with ongoing research aimed at overcoming their current limitations and expanding their applications. The key areas of focus include the following:

- Creating enhanced bacteriocins: Developments in synthetic biology and protein engineering may result in the creation of bacteriocins that are more stable, have a wider range of activity, or are less susceptible to resistance.
- Fighting Antibiotic Resistance: Bacteriocins provide an additional or substitute strategy for conventional antibiotics when antibiotic resistance continues to grow. Their specificity and distinct modes of action may make them useful in the treatment of resistant infections.
- Integration with Food Safety Procedures: Bacteriocins could be used more effectively to preserve food, possibly replacing chemical preservatives and lowering the risk of foodborne infections. Consumer acceptability and regulatory permissions are essential for their wide adoption.
- Agricultural Applications: By focusing on specific bacterial pathogens in agriculture, bacteriocins may be able to manage plant illnesses and enhance plant health while lowering the need for chemical pesticides.
- Personalized Medicine: As our knowledge of microbiomes grows, bacteriocins may be specially designed to regulate the microbiome of each person for various health advantages, such as the treatment of intestinal dysbiosis and other disorders linked to the microbiome.

Overall, bacteriocins hold significant promise as future antimicrobial strategies. Continued interdisciplinary research and collaboration are essential to unlocking their full potential and addressing global challenges in health, food security and environmental sustainability.

REFERENCES

1. Cotter, D., Hill, C., and Ross, R. P. (2005). Bacterial antibiotics: Strategies to improve therapeutic potential. *Current Protein and Peptide Science*, 6(1), 61–75.
2. Yang, S. C., Lin, C. H., Sung, C. T., and Fang, J. Y. (2014). Corrigendum: antibacterialactivitiesofbacteriocins:applicationinfoodsandpharmaceuticals.*FrontiersinMicrobiology*,*5*, 683.
3. Riley, M. A., and Wertz, J. E. (2002). Bacteriocin diversity: Ecological and evolutionary perspective *Biochimie*, 84(5–6), 357–364.
4. Cotter, P. D., Hill, C., and Ross, R. P. (2005). Bacteriocins: Developing innate immunity, *Nature Reviews Microbiology*, 3(10), 777–788.
5. Riley, M. A., Robinson, S. M., Roy, C. M., and Dorit, R. L. (2013). Rethinking the composition of a rational antibiotic arsenal for 21st century. *Future Medicinal Chemistry*, 5(11), 1231–1242.

6. Heng, N. C., Wescombe, P. A., Burton, J. P., Jack, R. W., and Tagg, J. R. (2007). The diversity of bacteriocins in gram-positive., *Bacteriocins: Ecology and Evolution* (pp. 45–92),. Berlin, Heidelberg: Springer Berlin Heidelberg.

7. Two-Component Systems in Bacteriocin Regulation (Marques *et al.,,* 2004) Explore the role of TCSs in regulating bacteriocin production., 102.

8. Kuipers, O. P., Beerthuyzen, M. M., de Ruyter, P. G., Luesink, E. J., and de Vos, W. M. (1995). Autoregulation of nisin biosynthesis in *Lactococcus lactis* by signal transduction. *Journal of Biological Chemistry*, 270(45), 27299–27304.

9. Perez-Velazquez, Golgeli, M., andGarcia-Contreras, R. (2016). Mathematical Modeling of Bacterial Quorum Sensing: A Review. *Bulletin Of Mathematical Biology*, 78, 1585–1639.

10. De Saizieu, A., Gardes, C., Flint, N., Wagner, C., Kamber, M., Mitchell, T. J. and Lange, (2000). Microarray-based identification of a novel Streptococcus pneumoniae regulon controlled by an auto-induced peptide. *Journal of Bacteriology*, 182(17), 4696–4703.

11. Guerra, Najera, J. L., Gonzalez, J. M., Lopez-Fernandez, L. A., Climent, N., Gatell, M., and Esteban, M. (2007). Distinct gene expression profiling after infection with immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. *Journal of Virology* 81(16): 8707–8721.

12. De Vuyst and Vandamme, J. (1994). Nisin, a lantibiotic produced by *Lactococcus lactis*subspecies lactis: Properties Such As Biosynthesis, Fermentation, And Applications., *Bacteriocins of Lactic Acid Bacteria: Microbiology, Genetics, and Applications*.,151-221.

13. Wang, C. Y., Patel, N., Wholey, W. Y., and Dawid, S. (2018). ABC transporter content diversity in Streptococcus pneumoniae impacts competence regulation and bacteriocin., *Proceedings of the National Academy of Sciences*, 115(25), E5776–E5785.

14. Ganzle, M. G., Hertel, C., van der Vossen, J. M., and Hammes, W. P. (1999). Effects of bacteriocin-producing lactobacilli on the survival of *Escherichia coli* and *Listeria* in a dynamic model of the stomach and small intestine. *International Journal of Food Microbiology* 48(1): 21–35.

15. Breukink and de Kruijff, B. (1999). The lantibiotic nisin: a special case or not? *Biochemical et Biophysical Acta (BBA)-Biomembranes*, 1462(1-2), 223-234.

16. Schneider, T. R., Karcher, J., Pohl, E., Lubini, P., and Sheldrick, G. M. (2000). Ab initio structure determination of the lantibiotic., *Acta Crystallographic Section D: Biological Crystallography*, 56(6), 705-713.

17. Collins, B. and Cotter, P. D., Hill, C., and Ross, P. (2010). Applications of lactic acid-producing bacteria.,*Biotechnology of Lactic Acid Bacteria*: *Novel Applications.* 89–10.

18. Hachard, Y., and Sahl, H. G. (2002). Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria. Biochimie, 84 (5–6), 545–557.

19. Morgan, M., O'Connor, P. M., Cotter, P. D., Ross, R. P., and Hill, C. (2005) The sequential actions of the two-component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrobial Agents and Chemotherapy, 49 (7), 2606–2611.

20. Gabrielsen, Brede, D. A., Salehian, Z., Nes, I. F., and Diep, D. B. (2014). Functional genetic analysis of the GarML gene cluster in *Lactococcus garvieae* DCC43 gives new insights into circular bacteriocin biosynthesis., *Journal of Bacteriology*, 196(5): 911–919.

21. Breukink and de Kruijff, B. (2006). Lipid II as a target for antibiotics. *Nature Reviews Drug Discovery*, 5(4), 321-323.

22. Altena, Guder, and A. Cramer, C., and Bierbaum, G. (2000). Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster. *Applied and Environmental Microbiology* 66(6): 2565–2571.

23. Gravesen, A., Jydegaard Axelsen, A. M., Mendes da Silva, J., Hansen, T. B., and Knochel, S. (2002). Frequency of bacteriocin resistance development and associated fitness costs in *Listeria monocytogenes*. *Applied and Environmental Microbiology*, 68(2), 756-764.

24. Davies and Davies, D. (2010). Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews 74(3): 417–433.

25. Chatterjee, C., Paul, M., Xie, L., and Van Der Donk, W. A. (2005). Biosynthesis and mode of action Chemical Reviews, 105(2), 633-684.

26. Sahl, G., Jack, R. W., and Bierbaum, G. (1995). Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. *European Journal of Biochemistry*, 230(3), 827-853.

27. Drider, D., Fimland, G., Hechard, Y., McMullen, L. M., Prévost, H. (2006). The continuing story of class IIa,*Microbiology, and molecular biology reviews*, 70(2), 564-582.

28. Cascales, E., Buchanan, S. K., Duché, D., Kleanthous, C., Lloubes, R., Postle, K. and Cavard, D. (2007). Colicin biology. *Microbiology and Molecular Biology Reviews* 71(1): 158–229.

29. Duquesne, S., Petit, V., Peduzzi, J., and Rebuffat, S. (2007). Structural and functional diversity of microcins and gene-encoded antibacterial peptides from the *Journal of Molecular Microbiology and Biotechnology*, 13(4), 200–209.

30. Nissen-Meyer, Oppegård, C., Rogne, P., Haugen, H. S., and Kristiansen, P. E. (2010). Structure and mode-of-action of the two-peptide (class-IIb) bacteriocins. *Probiotics and antimicrobial proteins*, 2, 52–60.

31. Eijsink, V. G., Skeie, M., Middelh oven, P. H., Brurberg, M. B., and Nes, I. F. (1998). Comparative studies of class IIa bacteriocins of lactic acid. *Applied and Environmental Microbiology* 64(9), 3275–3281.

32. Delves-Broughton (1990). Nisin and its use as a food preservative. Ennahar, Sashihara, T., Sonomoto, K., and Ishizaki, A. (2000). Class IIa bacteriocins: biosynthesis, structure, and activity. *FEMS Microbiology Reviews*, 24(1), 85–106.

33. Pugsley, A. P. and Schwartz, M. (1984). Colicin E2 release: lysis, leakage, or secretion? Possible role of The EMBO Journal, 3(10), 2393–2397.

34. Nes, F., *et al.,* (2015). "Bacteriocins of lactic acid bacteria: production, properties, and applications. *Applied Microbiology and Biotechnology*, 99(21), 9153–9166. DOI: 10.1007/s00203-015-1078-7.

35. O'Connor, Chouinard-Castonguay, S., Gagnon, C., and Rudkowska, I. (2017). Prebiotics are used in the management of components of the metabolic syndrome., Maturitas, 104, 11–18.

36. Yadav, M., & Chauhan, N. S. (2022). Microbiome therapeutics: exploring the present scenario and challenges. *Gastroenterology report*, *10*, goab046.

37. Evangelin Y, Venkateswarulu TC, John Babu D, Kasturi K. Bacteriocins from Lactic Acid Bacteria and Its Potential Applications. Int J Pharm Sci, 2015; 32: 306-309.

38. Mathur, H., Field, D., Rea, M. C., Cotter, P. D., Hill, C., & Ross, R. P. (2017). Bacteriocin-antimicrobial synergy: A medical and food perspective. Front. Microbiol. 8: 1205.

39. Meade, E., Slattery, M. A., & Garvey, M. (2020). Bacteriocins, potent antimicrobial peptides and the fight against multi drug resistant species: resistance is futile?. *Antibiotics*, *9*(1), 32.

40. Wang, Y., Wang, Y., Sun, T., & Xu, J. (2024). Bacteriocins in Cancer Treatment: Mechanisms and Clinical Potentials. *Biomolecules*, *14*(7), 831.

41. Guryanova, S. V. (2023). Immunomodulation, bioavailability and safety of bacteriocins. *Life*, *13*(7), 1521.

42. Benítez-Chao, D. F., León-Buitimea, A., Lerma-Escalera, J. A., & Morones-Ramírez, J. R. (2021). Bacteriocins: an overview of antimicrobial, toxicity, and biosafety assessment by in vivo models. *Frontiers in Microbiology*, *12*, 630695.

43. Srinivasan, R., Kumawat, D. K., Kumar, S., & Saxena, A. K. (2013). Purification and characterization of a bacteriocin from Lactobacillus rhamnosus L34. *Annals of microbiology*, *63*, 387-392.

44. López-Cuellar, M. D. R., Rodríguez-Hernández, A. I., & Chavarría-Hernández, N. (2016). LAB bacteriocin applications in the last decade. *Biotechnology & Biotechnological Equipment*, *30*(6), 1039-1050.

45. Mercado, V., & Olmos, J. (2022). Bacteriocin production by Bacillus species: Isolation, characterization, and application. *Probiotics and Antimicrobial Proteins*, *14*(6), 1151-1169.

46. Molujin, A. M., Abbasiliasi, S., Nurdin, A., Lee, P. C., Gansau, J. A., & Jawan, R. (2022). Bacteriocins as potential therapeutic approaches in the treatment of various cancers: A review of in vitro studies. *Cancers*, *14*(19), 4758.

47. Gu, Q. (2023). Agriculture. In: Bacteriocins. Springer, Singapore. https://doi.org/10.1007/978-981-99-2661-9_7

48. Soltani, S., Hammami, R., Cotter, P. D., Rebuffat, S., Said, L. B., Gaudreau, H., ... & Fliss, I. (2021). Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations. *FEMS microbiology reviews*, *45*(1), fuaa039.

49. Perez, R. H., Zendo, T., & Sonomoto, K. (2014). Novel bacteriocins from lactic acid bacteria (LAB): various structures and applications. *Microbial cell factories*, *13*, 1-13.